We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
Read MoreHide Full Article
Aeglea BioTherapeutics completed its acquisition of Spyre Therapeutics, Inc., a privately held company focused on developing antibody therapeutics for inflammatory bowel disease (IBD). Shares of Aeglea soared 329% on Jun 22, following the news.
Spyre’s lead programs include SPY001 and SPY002. While SPY001 targets a4b7, SPY002 targets TL1A. Clinical studies for Spyre's lead programs are set to begin in 2024. Management expects initial clinical results for SPY001 by 2024.
IBD is a chronic condition characterized by inflammation of the digestive tract. With approximately 1.7 million IBD patients in the United States alone, the global market for the same is expected to exceed $29 billion by 2028.
The aforementioned acquisition has enabled Aeglea to advance the treatment for IBD and capitalize on the growing market opportunity.
Shares of AGLE have risen 1.3% year to date against the industry’s 7.7% decline.
Image Source: Zacks Investment Research
The company also entered into a definitive agreement (with existing and new investors) for the sale of $210-million Series A non-voting convertible preferred stock through a private placement. These funds will be utilized to advance Spyre's portfolio of potential best-in-class IBD products through various data milestones.
Furthermore, the capital raised is expected to support Aeglea's operations until 2026. It will provide the company with financial stability as it continues to pursue its research and development efforts.
AGLE’s clinical pipeline includes pegzilarginase in a PEACE phase III study to treat patients with arginase 1 deficiency. In August 2022, the European Medicines Agency (EMA) accepted to review the marketing authorization application for pegzilarginase to treat arginase 1 deficiency.
The regulatory body is currently evaluating the application and a decision regarding the same is expected in late 2023.
The candidate received an Orphan Drug designation from the FDA and the EMA. It was also awarded the Fast Track and Breakthrough Therapy designations by the FDA for pegzilarginase to treat patients with arginase 1 deficiency.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $2.96 per share to a loss of $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 5.1% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss of 19 cents per share to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have risen 1.8% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus mark for Omega Therapeutics has narrowed from a loss of $2.51 per share to $2.05 for 2023 in the past 90 days. Shares of the company have rallied 26.1% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
Aeglea BioTherapeutics completed its acquisition of Spyre Therapeutics, Inc., a privately held company focused on developing antibody therapeutics for inflammatory bowel disease (IBD). Shares of Aeglea soared 329% on Jun 22, following the news.
Spyre’s lead programs include SPY001 and SPY002. While SPY001 targets a4b7, SPY002 targets TL1A. Clinical studies for Spyre's lead programs are set to begin in 2024. Management expects initial clinical results for SPY001 by 2024.
IBD is a chronic condition characterized by inflammation of the digestive tract. With approximately 1.7 million IBD patients in the United States alone, the global market for the same is expected to exceed $29 billion by 2028.
The aforementioned acquisition has enabled Aeglea to advance the treatment for IBD and capitalize on the growing market opportunity.
Shares of AGLE have risen 1.3% year to date against the industry’s 7.7% decline.
Image Source: Zacks Investment Research
The company also entered into a definitive agreement (with existing and new investors) for the sale of $210-million Series A non-voting convertible preferred stock through a private placement. These funds will be utilized to advance Spyre's portfolio of potential best-in-class IBD products through various data milestones.
Furthermore, the capital raised is expected to support Aeglea's operations until 2026. It will provide the company with financial stability as it continues to pursue its research and development efforts.
AGLE’s clinical pipeline includes pegzilarginase in a PEACE phase III study to treat patients with arginase 1 deficiency. In August 2022, the European Medicines Agency (EMA) accepted to review the marketing authorization application for pegzilarginase to treat arginase 1 deficiency.
The regulatory body is currently evaluating the application and a decision regarding the same is expected in late 2023.
The candidate received an Orphan Drug designation from the FDA and the EMA. It was also awarded the Fast Track and Breakthrough Therapy designations by the FDA for pegzilarginase to treat patients with arginase 1 deficiency.
Aeglea BioTherapeutics, Inc. Price and Consensus
Aeglea BioTherapeutics, Inc. price-consensus-chart | Aeglea BioTherapeutics, Inc. Quote
Zacks Rank and Other Stocks to Consider
Aeglea currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) , ADMA Biologics, Inc. (ADMA - Free Report) and Omega Therapeutics (OMGA - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $2.96 per share to a loss of $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 5.1% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss of 19 cents per share to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have risen 1.8% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus mark for Omega Therapeutics has narrowed from a loss of $2.51 per share to $2.05 for 2023 in the past 90 days. Shares of the company have rallied 26.1% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.